Product Images Tizanidine Hydrochloride

This is a description for Tizanidine Hydrochloride Capsules with NDC 72241-041-07. The capsules are interchangeable with tizanidine tablets or Zanaflex tablets. Each capsule contains 2.29 mg tizanidine hydrochloride, equivalent to 2 mg tizanidine base. The medication should be stored at 25°C (77°F) with excursions permitted between 15° to 30°C (59° to 86°F). It is a prescription medication dispensed in containers with child-resistant closure. The usual dosage is referred to the package insert for prescribing information. Zanaflex is a registered trademark of Acorda Therapeutics Inc. This medication is manufactured by Cadila Pharmaceuticals Limited in India and distributed by Modavar Pharmaceuticals LLC in Washington, DC.*

This is a description and label information for Tizanidine Hydrochloride Capsules, which contains 4.58mg of tizanidine hydrochloride per capsule, equivalent to 4mg of tizanidine base. It is indicated for muscle relaxation to treat muscle spasms caused by certain medical conditions. It is not interchangeable with tizanidine tablets or Zanaflex tablets. The usual dosage is outlined in the package insert for prescribing information. The medication should be stored between 15°C to 30°C (59°F to 86°F) and in child-resistant containers. Zanaflex is a registered trademark of Acorda Therapeutics Inc. The product is manufactured by Cadila Pharmaceuticals Limited in Gujarat, India and is distributed by Modavar Pharmaceuticals LLC. The medication requires a prescription and must be kept out of reach of children.*

This is a description of Tizanidine Hydrochloride Capsules used as medication. It contains 150 capsules each of 6.87mg of tizanidine hydrochloride, which is not interchangeable with tablets or Zanaflex. The usual dosage can be found in the package insert for prescribing information. The medication should be stored between 15° to 30°C (59° to 86°F) with a child-resistant closure. The manufacturer of the capsule is Cadila Pharmaceuticals Limited, while the medication is manufactured for Modavar Pharmaceuticals LLC. Zanaflex is a registered trademark of Acorda Therapeutics Inc.*

This text shows data about the improvement in Ashworth score during a study that compared the effects of Tizanidine (at a mean dose of 28.8mg) with placebo. The study lasted for 7 weeks, with the end of titration being at week 3 and the end of maintenance endpoint being at week 7. The study seeks to evaluate the effectiveness of Tizanidine in reducing Ashworth score.*